Maternal Respiratory Syncytial Virus Vaccine Preparedness Quality and Innovation Collective
Maternal Respiratory Syncytial Virus (RSV) Vaccine Preparedness Quality and Innovation Collective (QuIC)
AMGA’s new Quality and Innovation Collective (QuIC) on Maternal Respiratory Syncytial Virus (RSV) Vaccine Preparedness aims to improve care of infants at risk for RSV by maternal RSV vaccination and to raise awareness of the burden of RSV disease.
- According to the Centers for Disease Control and Prevention (CDC), each year in the United States, RSV leads to approximately 58,000-80,000 hospitalizations among children younger than 5 years old.
- On August 21, 2023, the Food and Drug Administration approved the first vaccine for use against RSV during the 32 to 36 weeks of pregnancy to protect infants from birth through 6 months of age. On September 22, 2023, CDC's Advisory Committee on Immunization Practices (ACIP) issued routine recommendations for its use, and these recommendations have been published in the Morbidity and Mortality Weekly Report (MMWR) following signoff by the CDC director.
AMGA’s Maternal RSV QuIC is a three-phase initiative, combining an educational webinar and virtual discussion forum, a one-day virtual meeting, and a two-day in-person meeting. This QuIC utilizes interactive workshops with quality improvement tools and qualitative methodology to engage AMGA member organizations in thoughtful discussions to collect insights and share best practices on creating and implementing successful immunization rollout strategies at their organizations.
Opportunity
Up to 10 medical groups and health systems in maternal and infant health clinic settings, which are knowledgeable about bringing a new vaccine into their organization’s workflow, are eligible to participate. Individuals are not required to be knowledgeable about the RSV vaccination to participate.
Participating AMGA member groups will be asked to identify two team members in maternal and infant health to participate throughout the program, as each phase discussion will build upon the last. Team member roles include, but are not limited to physician, quality leader, advanced practice provider, medical director, and other roles associated with immunizations.
Details for the RSV QuIC
.jpg){kind=icon}
November & December 2023
Listen and engage in:
- A live 1-hour educational webinar on maternal RSV vaccine
- Vaccine program within your organizations
- Click here to download the QuIC Phase 1 Meeting Summary
.jpg){kind=icon}
May 2024
Share in educational sessions and interactive activities current practices of bringing a new vaccine into the organization's workflow, barriers, and plans for implementation of tailored interventions
_2.jpg){kind=icon}
October 2024
Create and engage in:
-
A meeting on your organization's next steps for a newly approved vaccine
-
Hands-on and interactive learning with direct goals and objectives
-
A meeting that will incorporate group work, roundtables, panels, and lecture presentations, and offers participants opportunities to collaborate with one another in a structured learning environment
Benefits of Participation
- Participating organizations will receive a $5,000 honorarium.
- Exclusive opportunity to engage in interactive discussion with AMGA members and vaccination experts.
- Incorporate quality improvement techniques, best practices, operational tips and tools, and resources from other leading medical groups and health systems on creating successful immunization rollout strategies at their organizations.
- Improve value through better patient care and outcomes (quality and value).
- A best practices summary highlighting your insights from each meeting will be published.
If your organization is interested in learning more, please contact Senait Temesgen, (stemesgen@amga.org)
